Wells Fargo & Company Boosts Ascendis Pharma A/S (NASDAQ:ASND) Price Target to $289.00

Ascendis Pharma A/S (NASDAQ:ASND) had its target price raised by Wells Fargo & Company from $264.00 to $289.00 in a research report report published on Tuesday morning, Benzinga reports. Wells Fargo & Company currently has an overweight rating on the biotechnology company’s stock.

A number of other analysts have also weighed in on ASND. Cantor Fitzgerald reiterated an overweight rating and set a $170.00 target price on shares of Ascendis Pharma A/S in a report on Monday. StockNews.com upgraded Ascendis Pharma A/S from a sell rating to a hold rating in a report on Thursday, September 5th. Citigroup cut their price objective on Ascendis Pharma A/S from $193.00 to $178.00 and set a buy rating on the stock in a research report on Wednesday, September 4th. Oppenheimer restated an outperform rating and set a $190.00 target price (up previously from $180.00) on shares of Ascendis Pharma A/S in a report on Tuesday. Finally, JPMorgan Chase & Co. cut their price target on shares of Ascendis Pharma A/S from $174.00 to $165.00 and set an overweight rating on the stock in a report on Wednesday, September 4th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of Moderate Buy and a consensus target price of $193.77.

Ascendis Pharma A/S Stock Up 3.1 %

NASDAQ:ASND opened at $153.43 on Tuesday. The firm has a market capitalization of $8.93 billion, a P/E ratio of -15.49 and a beta of 0.63. Ascendis Pharma A/S has a 52 week low of $85.29 and a 52 week high of $161.00. The company has a fifty day moving average of $132.94 and a 200 day moving average of $136.52.

Institutional Trading of Ascendis Pharma A/S

A number of hedge funds and other institutional investors have recently modified their holdings of ASND. Quarry LP boosted its stake in Ascendis Pharma A/S by 257.1% during the second quarter. Quarry LP now owns 2,500 shares of the biotechnology company’s stock worth $341,000 after acquiring an additional 1,800 shares in the last quarter. Algert Global LLC lifted its holdings in shares of Ascendis Pharma A/S by 54.6% during the second quarter. Algert Global LLC now owns 2,180 shares of the biotechnology company’s stock valued at $297,000 after purchasing an additional 770 shares during the last quarter. Lighthouse Investment Partners LLC bought a new stake in shares of Ascendis Pharma A/S in the 2nd quarter worth approximately $2,762,000. Fred Alger Management LLC grew its stake in shares of Ascendis Pharma A/S by 65.0% in the 2nd quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company’s stock worth $41,879,000 after buying an additional 120,952 shares during the last quarter. Finally, First Light Asset Management LLC bought a new position in Ascendis Pharma A/S during the 2nd quarter valued at approximately $4,931,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.